Partial Thromboplastin Time
"Partial Thromboplastin Time" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.
Descriptor ID |
D010314
|
MeSH Number(s) |
E01.370.225.625.115.600 E05.200.625.115.600 G09.188.660
|
Concept/Terms |
Kaolin-Cephalin Coagulation Time- Kaolin-Cephalin Coagulation Time
- Coagulation Time, Kaolin-Cephalin
- Kaolin Cephalin Coagulation Time
- Coagulation Time, Cephalin-Kaolin
- Coagulation Time, Cephalin Kaolin
- Cephalin-Kaolin Coagulation Time
- Cephalin Kaolin Coagulation Time
|
Below are MeSH descriptors whose meaning is more general than "Partial Thromboplastin Time".
Below are MeSH descriptors whose meaning is more specific than "Partial Thromboplastin Time".
This graph shows the total number of publications written about "Partial Thromboplastin Time" by people in this website by year, and whether "Partial Thromboplastin Time" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 2 | 2 |
1996 | 0 | 4 | 4 |
1997 | 0 | 1 | 1 |
1998 | 0 | 1 | 1 |
2000 | 1 | 0 | 1 |
2002 | 1 | 2 | 3 |
2003 | 1 | 0 | 1 |
2004 | 0 | 1 | 1 |
2006 | 0 | 2 | 2 |
2007 | 0 | 1 | 1 |
2008 | 0 | 1 | 1 |
2010 | 0 | 2 | 2 |
2012 | 0 | 1 | 1 |
2016 | 1 | 0 | 1 |
2017 | 0 | 1 | 1 |
2019 | 0 | 1 | 1 |
2021 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Partial Thromboplastin Time" by people in Profiles.
-
Interlaboratory Performance in Measurement of Dabigatran and Rivaroxaban. Arch Pathol Lab Med. 2022 01 02; 146(2):145-153.
-
Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2021 May; 8(5):e334-e343.
-
Controversies in anticoagulation therapy in patients with cirrhosis. Curr Opin Gastroenterol. 2019 05; 35(3):161-167.
-
Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications. Pharmacotherapy. 2017 Apr; 37(4):393-400.
-
Effect of Subcutaneous Unfractionated Heparin Prophylaxis on Activated Partial Thromboplastin Time: A Retrospective Evaluation. J Clin Anesth. 2016 Sep; 33:346-50.
-
Safety and effectiveness outcomes of an inpatient collaborative drug therapy management service for direct thrombin inhibitors. Am J Health Syst Pharm. 2012 Nov 15; 69(22):1993-8.
-
Improvement in long-term ECMO by detailed monitoring of anticoagulation: a case report. Perfusion. 2011 Jan; 26(1):59-64.
-
Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost. 2010 Nov; 104(5):976-83.
-
Use of bivalirudin to prevent thrombosis following orthotopic liver transplantation in a patient with Budd-Chiari syndrome and a history of heparin-induced thrombocytopenia. Ann Clin Lab Sci. 2008; 38(3):277-82.
-
Cutaneous and systemic effects of varying doses of brown recluse spider venom in a rabbit model. Clin Lab Sci. 2007; 20(2):99-105.